NO20081733L - Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling - Google Patents

Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling

Info

Publication number
NO20081733L
NO20081733L NO20081733A NO20081733A NO20081733L NO 20081733 L NO20081733 L NO 20081733L NO 20081733 A NO20081733 A NO 20081733A NO 20081733 A NO20081733 A NO 20081733A NO 20081733 L NO20081733 L NO 20081733L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
preparation
controlled release
release pharmaceutical
venlafaxine hydrochloride
Prior art date
Application number
NO20081733A
Other languages
English (en)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Original Assignee
Valpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma Sa filed Critical Valpharma Sa
Publication of NO20081733L publication Critical patent/NO20081733L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en kontrollert fiigjørende farmasøytisk sammensetning av venlafaksinhydroklorid, et effektivt antidepressivt middel, som omfatter en inert kjerne på hvilken det ensartet er pålagt det aktive prinsippet, som så igjen er belagt med et lag som omfatter et herdingsmiddel og et lipofilt middel; foruten at fremgangsmåten for fremstillingen av nevnte farmasøytiske sammensetning også er beskrevet.
NO20081733A 2005-09-30 2008-04-07 Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling NO20081733L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITFI20050206A1 (it) 2005-09-30 2005-09-30 Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
PCT/EP2006/066906 WO2007039569A2 (en) 2005-09-30 2006-09-29 Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof

Publications (1)

Publication Number Publication Date
NO20081733L true NO20081733L (no) 2008-04-07

Family

ID=36215990

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081733A NO20081733L (no) 2005-09-30 2008-04-07 Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling

Country Status (17)

Country Link
US (1) US20090263471A1 (no)
EP (1) EP1928424B1 (no)
JP (1) JP2009510027A (no)
KR (1) KR20080047557A (no)
CN (1) CN101257893A (no)
AT (1) ATE521339T1 (no)
AU (1) AU2006298693A1 (no)
BR (1) BRPI0616276A2 (no)
CA (1) CA2622822A1 (no)
ES (1) ES2373164T3 (no)
IL (1) IL190305A0 (no)
IT (1) ITFI20050206A1 (no)
NO (1) NO20081733L (no)
NZ (1) NZ567735A (no)
RU (1) RU2423105C2 (no)
WO (1) WO2007039569A2 (no)
ZA (1) ZA200803502B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
HUE063590T2 (hu) 2007-04-25 2024-01-28 Eirgen Pharma Ltd Szabályozott felszabadulású 25-hidroxi-D-vitamin
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
CN103181916A (zh) * 2011-12-30 2013-07-03 昆明积大制药股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20170047265A (ko) 2014-08-07 2017-05-04 옵코 아일랜드 글로벌 홀딩스 리미티드 25-하이드록시비타민 d를 이용한 보조요법
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci

Also Published As

Publication number Publication date
WO2007039569A2 (en) 2007-04-12
ES2373164T3 (es) 2012-02-01
ATE521339T1 (de) 2011-09-15
ZA200803502B (en) 2009-01-28
EP1928424A2 (en) 2008-06-11
CA2622822A1 (en) 2007-04-12
RU2423105C2 (ru) 2011-07-10
AU2006298693A1 (en) 2007-04-12
US20090263471A1 (en) 2009-10-22
KR20080047557A (ko) 2008-05-29
RU2008117111A (ru) 2009-11-10
ITFI20050206A1 (it) 2007-04-01
JP2009510027A (ja) 2009-03-12
NZ567735A (en) 2011-03-31
WO2007039569A3 (en) 2007-07-26
EP1928424B1 (en) 2011-08-24
BRPI0616276A2 (pt) 2011-06-14
IL190305A0 (en) 2009-09-22
CN101257893A (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
NO20081733L (no) Kontrollert frigjorende farmasoytisk sammensetning av venlafaksinhydroklorid og fremgangsmate for dens fremstilling
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2009000903A1 (es) Composiciones farmacéuticas que comprenden un núcleo que contiene una droga débilmente básica seleccionada de derivados de butirofenona, una capa de amortiguador de ph alcalino y un recubrimiento de liberación controlada, método para preparar dichas composiciones y formas de dosificación farmacéutica que las incluyen.
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007002358A1 (es) Sistema de liberacion farmaceutica controlado, oral que comprende uno o mas modificadores de ph, una capa aislante; procedimiento de preparacion; y su uso para el tratamiento de trastornos del sistema nervioso central, sistema afectivo, del sueno y s
HUP0500540A2 (hu) Vanlafaxin-hidrokloridot tartalmazó, nyújtott hatóanyag-leadású készítmények
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
MX345777B (es) Formulaciones de tabletas bicapa.
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
WO2009059701A3 (de) Retardtabletten mit hydromorphon
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
DE122012000030I1 (de) Wirkstoffhaltige feste formkorper zur auserlichen anwendung gegen parasiten an tieren.
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
HK1118043A1 (en) Coated fertiliser with a controlled release of active ingredients, and method for the production thereof
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
BRPI0920683A2 (pt) Composto, composição de composto ativo, semente, medicamento, e, métodos para controlar fungos fitopatogênicos, e para preparar um agente antimicótico
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application